Navigation Links
HARD TO TREAT DISEASES (HTDS) Influenca Vaccine (MEVAC-FLU) Enters Chilean Market

SHENZEN, China, March 20 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS) is pleased to announce that the first batch of Influenca Vaccine (MEVAC-FLU) entered Chilean market. The company will also attend the tender of 2.5 million doses of influenza vaccine for Chile in 2009.

Terry Yuan CEO of HTDS said, "After two years of hard work, we have finished the registration of the influenza vaccine in Chile. The ISP (Instituto De Salud Publica de Chile) issued the GMP certificate to our plant after a strict inspection in June, 2008. In Dec. 2008, we obtained the registration certificate successfully. Now, in Feb.2009, we have exported the first lot of 25,000 units of influenza vaccine (Brand name: Mevac Flu) to Chile. This is the first time for Chinese influenza vaccine to enter the Chilean market. We see this as a good opportunity to open up the South American market for us as a company.

"The Chilean government has a tender project each year for influenza vaccine of 1.5-2.7 million doses. This is a free vaccination for the elder people. In Sep. 2009, Mellow Hope will participate to bid the tender of 2.5 million doses. Since the first lot is being used by the local people, once the vaccine is well-approved, it will be helpful for Mellow Hope to bid the tender."

The company will provide further details as they become available.

Get the Facts Right. The issuer works hard to continue to keep our shareholders informed, and news is updated frequently via Press Releases, Pink Sheet filings, and updates to our websites. Other websites not sponsored, or recognized by the Company may provide misleading or disinformation to investors in order to manipulate trading patterns for a given stock. Always look for original content from trusted sources, rather than relying on 'excerpts' or discussion boards that may not give you the whole story. The Securities and Exchange Commission requires financial institutions or brokerage firms to provide their clients with documentation, describing the risks of investing in penny stocks.

CONTACT: For medical and scientific dialogue inquiry only, please contact Andrea Zecevic Hbsc. Msci via e-mail at Andrea Zecevic obtained her degrees at the University of Toronto Canada. Andrea Zecevic is the company's Chief Project Scientist, R&D and the Chief Liaison Director between the China and Serbia operating subsidiaries. For any corporate matters, readers should contact the company directly at

SOURCE Hard to Treat Diseases
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Pelosi Statement on Reintroduction of the Early Treatment for HIV Act
2. Forest Laboratories, Inc. Announces FDA Approval of Lexapro(R) for the Treatment of Major Depressive Disorder in Adolescents
3. Final Patient Completes Treatment In Boehringer Ingelheims RE-LY(R) Study, The Largest Atrial Fibrillation Outcomes Trial To Date
4. Maggots as Good as Gel in Leg Ulcer Treatments
5. New Parkinsons Treatment Shows Promise in Animals
6. Less is more when it comes to treating high blood pressure
7. Scientists trial device to treat chemotherapy-related nausea
8. Khloe Kardashian Receives Body Contouring VelaShape(TM) Treatment Before Photo Shoot
9. Free Community Seminar to Review Treatment Options for Enlarged Prostate
10. Japan Treats First Extracranial Patients Using CyberKnife Radiosurgery
11. New Clinical Study News for Treatment of Sinusitis - Sinus Infection and Allergy Suffers Now Have a New Effective Form of Relief through Sinus Dynamics
Post Your Comments:
(Date:11/27/2015)... ... 27, 2015 , ... Avid collector, Andrew Hawley from Vintage Rock Posters, announces ... This is one of Joplin's most famous and beautiful concert posters. The concert was ... in Ann Arbor. The According to Hawley, "It is hard to believe that Joplin's ...
(Date:11/26/2015)... MI (PRWEB) , ... November 26, 2015 , ... ... for substance abuse located in central Michigan, have come together on Thanksgiving Day ... specially produced video, available for viewing on the Serenity Point YouTube channel, patients ...
(Date:11/26/2015)... Toronto, ON and Cambridge, ON (PRWEB) , ... ... ... announced today the availability of a real-time eReferral system for diagnostic imaging in ... CTs, ultrasounds, X-rays, mammography, BMD and Nuclear Medicine tests directly from their electronic ...
(Date:11/26/2015)... ... ... The Catalent Applied Drug Delivery Institute today announced a ... selection in early phase drug development. The first of these is to be ... UK’s emerging life sciences companies, corporate partners, and investors, at Milton Park, Oxford, ...
(Date:11/26/2015)... San Antonio, TX (PRWEB) , ... November 26, 2015 , ... ... accomplishment! On November 19, 2015, our surgeons performed their 6,000th free flap breast ... Ledoux , “We wake up every day excited to rebuild lives and it’s an ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... , November 26, 2015 ... of the "Radioimmunoassay Market by Type ... Pharmaceutical Industry, Academics, Clinical Diagnostic Labs), Application ... Forecast to 2020" report to their ... announced the addition of the "Radioimmunoassay ...
(Date:11/25/2015)... , Nov. 25, 2015 ... addition of the "Global Brain Monitoring ... offering. --> ) has ... Brain Monitoring Devices Market 2015-2019" report ... and Markets ( ) has announced ...
(Date:11/25/2015)... Nov. 25, 2015  Amgen (NASDAQ: AMGN ) ... (BLA) with the United States ... a biosimilar candidate to Humira ® (adalimumab). Amgen ... submitted to the FDA and represents Amgen,s first BLA ... E. Harper , M.D., executive vice president of Research ...
Breaking Medicine Technology: